Further, Iridex will acquire the design and manufacturing operation of Topcon’s PASCAL® product line. direct sales and rest- of-world distribution network. Concurrently, Iridex will add Topcon’s PASCAL® systems to its U.S. Under the terms of these agreements, Topcon will acquire exclusive distribution of Iridex laser systems, delivery devices and disposable probes to be sold through its strong networks in Asia Pacific and key EMEA regions. The comprehensive collaboration between Iridex and Topcon includes three main agreements: an Exclusive Distribution Agreement, an Asset Purchase Agreement and an Equity Funding Agreement. Iridex acquires Topcon’s PASCAL® product line, combining Iridex’ MicroPulse® technology with Topcon’s PASCAL® laser platform, resulting in a leading market share for retinal scanning laser products, plus greater scale to generate design, manufacturing and marketing efficiencies.Iridex product portfolio to benefit from Topcon’s distribution strength in Asia Pacific and key EMEA markets, joining Topcon’s broad offering of diagnostic and treatment products for glaucoma and retina customers.Topcon invests in Iridex by i) purchasing exclusive rights to distribute Iridex’s retina and glaucoma products in certain global markets, and ii) acquiring a common equity stake of approximately 10.4% in Iridex.The transaction nets $19.5 million of cash to Iridex, providing multiyear funding for strategic growth initiatives, particularly those designed to drive expanded market penetration of Iridex’s unique non-incisional glaucoma therapy products.Highlights of the new strategic relationship include: ![]() Topcon is a Japanese-based manufacturer and distributor with approximately $1.3 billion in annual revenues, including $430 million from its eye care business. Mountain View, CA - MaIridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that it has entered into a strategic collaboration with Topcon Corporation. Iridex to host a conference call presentation on Maat 2:00 p.m.Transaction provides $19.5 million cash to Iridex, as two leaders join forces in glaucoma and retinal disease treatment.
0 Comments
Leave a Reply. |